Immunic (NASDAQ:IMUX) Announces Quarterly Earnings Results

Immunic (NASDAQ:IMUX) announced its quarterly earnings results on Tuesday. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36, FiscalAI reports.

Immunic Price Performance

Immunic stock traded down $0.12 during mid-day trading on Tuesday, reaching $13.98. 24,017 shares of the company traded hands, compared to its average volume of 281,369. The firm’s fifty day moving average is $14.29 and its two-hundred day moving average is $11.84. The company has a market capitalization of $190.41 million, a price-to-earnings ratio of -2.57 and a beta of 1.41. Immunic has a fifty-two week low of $5.06 and a fifty-two week high of $15.84.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus set a $25.00 price objective on Immunic and gave the company a “buy” rating in a research report on Thursday, April 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. Wolfe Research initiated coverage on shares of Immunic in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock. Wall Street Zen cut shares of Immunic from a “hold” rating to a “sell” rating in a research report on Sunday, April 19th. Finally, LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a report on Wednesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $47.57.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently made changes to their positions in the company. Qube Research & Technologies Ltd purchased a new stake in Immunic during the 3rd quarter valued at about $29,000. Two Sigma Investments LP acquired a new position in Immunic in the 3rd quarter worth approximately $52,000. Virtu Financial LLC purchased a new position in Immunic during the 3rd quarter worth approximately $99,000. XTX Topco Ltd acquired a new stake in Immunic during the 4th quarter valued at approximately $120,000. Finally, Jane Street Group LLC boosted its holdings in shares of Immunic by 46.8% in the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock valued at $153,000 after acquiring an additional 91,346 shares during the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.